Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK revises Avandia labeling
The existing boxed warning has been revised to add the FDA’s conclusion that, while an FDA meta-analysis of short-term studies, mostly against placebo, showed an association between Avandia
The existing boxed warning has been revised to add the FDA’s conclusion that, while an FDA meta-analysis of short-term studies, mostly against placebo, showed an association between Avandia
The company expects to announce results from the trial in late 2008. CERE-120 is designed to deliver the neurturin gene, a nervous system growth factor with the ability
Invitrogen’s patent applications which are part of this agreement cover stealth and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA. Dr Tod Woolf, president
Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing. The trial, known as MATRIX (GAM501 for the
Christopher Reinhard, chairman and CEO of Cardium and InnerCool, said: “Cardium and InnerCool recently announced the launch of the new CoolBlue surface-based patient temperature modulation system and expect
Including the over-allotment, the company sold 11.5 million shares in the offering, resulting in net proceeds of approximately $83.4 million after deducting the underwriting discounts and commission and
Cyberkinetics and NeuroMetrix have also agreed to negotiate a joint venture to develop and commercialize a therapeutic product for peripheral nerve injury based on Cyberkinetics’ Andara Oscillating Field
Patients undergoing laser treatment were 33% more likely to experience pain and 50% more likely to require postoperative pain medication than patients who received the ClosureFast treatment. The
The project, combining Isis’ know-how and IP in antisense chemistry and Rosetta Genomics’ knowhow and proprietary microRNA platform technologies, is the companies’ attempt at harnessing microRNAs’ role as
In the clinical study, 52 frozen samples taken from Alzheimer’s disease patients and age-matched controls, with an average age of 70 years were analyzed on a blinded basis